Adamas Pharmaceuticals (ADMS) Upgraded by BidaskClub to Sell
BidaskClub upgraded shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from a strong sell rating to a sell rating in a research report sent to investors on Friday morning.
Other analysts have also issued research reports about the company. HC Wainwright set a $40.00 price target on Adamas Pharmaceuticals and gave the company a buy rating in a report on Monday, January 14th. Zacks Investment Research upgraded Adamas Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, February 7th. Leerink Swann started coverage on Adamas Pharmaceuticals in a report on Monday, November 12th. They issued an outperform rating and a $20.00 price target for the company. Cowen set a $30.00 price target on Adamas Pharmaceuticals and gave the company a buy rating in a report on Thursday, November 1st. Finally, Mizuho lowered Adamas Pharmaceuticals from a buy rating to a neutral rating and lowered their price target for the company from $75.00 to $18.00 in a report on Monday, November 5th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. Adamas Pharmaceuticals presently has an average rating of Hold and a consensus target price of $31.25.
Shares of ADMS traded up $0.61 during mid-day trading on Friday, reaching $10.53. 632,093 shares of the company’s stock traded hands, compared to its average volume of 460,547. The stock has a market cap of $287.85 million, a price-to-earnings ratio of -2.65 and a beta of 1.41. Adamas Pharmaceuticals has a 12 month low of $7.42 and a 12 month high of $34.72. The company has a debt-to-equity ratio of 1.01, a quick ratio of 8.74 and a current ratio of 8.95.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Recommended Story: What is the Bid-Ask Spread?
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.